WS #14979
Merck has signed an exclusive global license agreement with SciBrunch Therapeutics for its investigational oral KRAS G12D inhibitor, SPR2015, for a $400M upfront payment plus milestones. This significant M&A activity in the oncology space highlights continued investment in targeted cancer therapies. Concurrently, Eton Pharmaceuticals announced the US commercial availability of IMPAVIDO, expanding its portfolio in rare disease treatments.
Biotech and Pharma M&A Activity
Merck has signed an exclusive global license agreement with SciBrunch Therapeutics for its investigational oral KRAS G12D inhibitor, SPR2015, for a $400M upfront payment plus milestones. This significant M&A activity in the oncology space highlights continued investment in targeted cancer therapies. Concurrently, Eton Pharmaceuticals announced the US commercial availability of IMPAVIDO, expanding its portfolio in rare disease treatments.